Helical nanoparticles trigger cancer alarms and deliver gene therapy

Scientists at South Korea’s Korea Advanced Institute of Science and Technology (KAIST) have developed a novel type of nanoparticle capable of triggering immune responses against cancer while simultaneously delivering gene therapy. The innovation, described in a study published in the journal Biomaterials, involves helical-shaped polypeptide nanoparticles designed to exploit vulnerabilities in cancer cells' defenses and enhance the effectiveness of immunotherapy. The research team, led by Professor Yeu-Chun Kim from KAIST’s Department of Chemical and Biomolecular Engineering, engineered these nanoparticles to induce a form of programmed cell death known as immunogenic cell death (ICD). ICD occurs when dying cancer cells release distress signals called damage-associated molecular patterns (DAMPs), alerting the immune system to their presence. These signals prompt immune cells to identify and destroy the cancerous cells. The new nanoparticles achieve this by creating internal stress within the cancer cells, leading to their demise and subsequent signaling to the immune system. The design of the nanoparticles plays a crucial role in their effectiveness. Unlike traditional spherical nanoparticles, the helical structure allows the particles to interact more efficiently with the cell membrane. Specifically, the nanoparticles incorporate a positively charged quaternary amine, a chemical component that binds easily to cell membranes. When combined with the helical shape, this feature enables the particles to penetrate the cell membrane like a screw, allowing them to enter cancer cells more effectively than non-helical counterparts with identical chemical compositions. Once inside the cancer cell, the nanoparticles target mitochondrial and other organelle membranes, causing significant disruption. This disruption leads to severe cellular stress, ultimately resulting in the release of DAMPs. These signals act as a beacon for the immune system, drawing attention to the previously undetected cancer cells and initiating an immune response. Beyond triggering immune recognition, the nanoparticles also serve as efficient carriers for gene-based therapies. They successfully deliver messenger RNA (mRNA) and small interfering RNA (siRNA) into the cytoplasm of cancer cells. mRNA provides instructions for producing proteins, while siRNA can silence specific genes. Delivering these genetic materials into cells is typically challenging due to the barriers posed by cell membranes and intracellular environments. However, the helical nanoparticles overcome these obstacles, ensuring effective delivery of the therapeutic payloads. To optimize stability and functionality, the researchers incorporated guanidinium, a chemical group that strongly interacts with genetic material. This addition helped maintain the structural integrity of the nanoparticles during circulation in the bloodstream while facilitating the targeted delivery of gene therapeutics. Experimental trials using mouse models demonstrated promising results. In models of melanoma and colorectal cancer, the nanoparticles were loaded with siRNA targeting PD-L1, a protein that cancer cells often use to evade immune detection. The treatment significantly suppressed tumor growth, suggesting potential applications in human cancer therapy. The dual function of the nanoparticles, triggering immune responses and delivering gene therapy, represents a major advancement in cancer treatment strategies. Traditional approaches often rely on separate methods for immunotherapy and gene therapy, requiring multiple treatments and potentially increasing side effects. This new platform offers a unified solution that could improve patient outcomes by combining two critical aspects of cancer care into a single, efficient delivery mechanism. Further studies will focus on refining the nanoparticle design for clinical application and evaluating its safety and efficacy in human trials. Researchers aim to explore how variations in the helical structure or chemical components might influence performance in different types of cancers. If successful, this technology could pave the way for more personalized and effective cancer treatments tailored to individual patients' needs.